Bivona G, Iemmolo M, Ghersi G
Int J Mol Sci. 2023; 24(23).
PMID: 38069230
PMC: 10706963.
DOI: 10.3390/ijms242316908.
Kang J, Korecka M, Lee E, Cousins K, Tropea T, Chen-Plotkin A
Clin Chem. 2023; 69(11):1247-1259.
PMID: 37725909
PMC: 10895336.
DOI: 10.1093/clinchem/hvad139.
Giangrande C, Delatour V, Andreasson U, Blennow K, Gobom J, Zetterberg H
Alzheimers Dement (Amst). 2023; 15(3):e12465.
PMID: 37600860
PMC: 10432775.
DOI: 10.1002/dad2.12465.
Huang S, Wang Y, Guo J
Neurosci Bull. 2022; 38(6):677-691.
PMID: 35306613
PMC: 9206048.
DOI: 10.1007/s12264-022-00836-7.
Korecka M, Shaw L
J Neurochem. 2021; 159(2):211-233.
PMID: 34244999
PMC: 9057379.
DOI: 10.1111/jnc.15465.
Developing the ATX(N) classification for use across the Alzheimer disease continuum.
Hampel H, Cummings J, Blennow K, Gao P, Jack Jr C, Vergallo A
Nat Rev Neurol. 2021; 17(9):580-589.
PMID: 34239130
DOI: 10.1038/s41582-021-00520-w.
Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status.
Willemse E, Tijms B, van Berckel B, Le Bastard N, van der Flier W, Scheltens P
Alzheimers Dement (Amst). 2021; 13(1):e12182.
PMID: 33969174
PMC: 8088096.
DOI: 10.1002/dad2.12182.
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis.
West T, Kirmess K, Meyer M, Holubasch M, Knapik S, Hu Y
Mol Neurodegener. 2021; 16(1):30.
PMID: 33933117
PMC: 8088704.
DOI: 10.1186/s13024-021-00451-6.
Alzheimer's disease.
Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chetelat G, Teunissen C
Lancet. 2021; 397(10284):1577-1590.
PMID: 33667416
PMC: 8354300.
DOI: 10.1016/S0140-6736(20)32205-4.
First amyloid β1-42 certified reference material for re-calibrating commercial immunoassays.
Boulo S, Kuhlmann J, Andreasson U, Brix B, Venkataraman I, Herbst V
Alzheimers Dement. 2020; 16(11):1493-1503.
PMID: 32755010
PMC: 7984389.
DOI: 10.1002/alz.12145.
Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease.
Leitao M, Silva-Spinola A, Santana I, Olmedo V, Nadal A, Le Bastard N
Alzheimers Res Ther. 2019; 11(1):91.
PMID: 31759396
PMC: 6875031.
DOI: 10.1186/s13195-019-0550-8.
Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays.
Schauer S, Mylott Jr W, Yuan M, Jenkins R, Mathews W, Honigberg L
Alzheimers Res Ther. 2018; 10(1):118.
PMID: 30486870
PMC: 6264029.
DOI: 10.1186/s13195-018-0445-0.
Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease.
Kruse N, Heslegrave A, Gupta V, Foiani M, Villar-Pique A, Schmitz M
Alzheimers Dement (Amst). 2018; 10:461-470.
PMID: 30294658
PMC: 6171371.
DOI: 10.1016/j.dadm.2018.06.005.
Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
Gangishetti U, Howell J, Perrin R, Louneva N, Watts K, Kollhoff A
Alzheimers Res Ther. 2018; 10(1):98.
PMID: 30253800
PMC: 6156847.
DOI: 10.1186/s13195-018-0426-3.
Automation vs. Experience: Measuring Alzheimer's Beta-Amyloid 1-42 Peptide in the CSF.
Kollhoff A, Howell J, Hu W
Front Aging Neurosci. 2018; 10:253.
PMID: 30186152
PMC: 6113375.
DOI: 10.3389/fnagi.2018.00253.
Round robin study of formalin-fixed paraffin-embedded tissues in mass spectrometry imaging.
Buck A, Heijs B, Beine B, Schepers J, Cassese A, Heeren R
Anal Bioanal Chem. 2018; 410(23):5969-5980.
PMID: 29968108
PMC: 6096706.
DOI: 10.1007/s00216-018-1216-2.
The Past and the Future of Alzheimer's Disease Fluid Biomarkers.
Blennow K, Zetterberg H
J Alzheimers Dis. 2018; 62(3):1125-1140.
PMID: 29562534
PMC: 5869995.
DOI: 10.3233/JAD-170773.
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.
Lewczuk P, Riederer P, OBryant S, Verbeek M, Dubois B, Visser P
World J Biol Psychiatry. 2017; 19(4):244-328.
PMID: 29076399
PMC: 5916324.
DOI: 10.1080/15622975.2017.1375556.
Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients.
Bridel C, Hoffmann T, Meyer A, Durieux S, Koel-Simmelink M, Orth M
Alzheimers Res Ther. 2017; 9(1):38.
PMID: 28587659
PMC: 5461753.
DOI: 10.1186/s13195-017-0266-6.
Alzheimer disease: CSF biomarkers for Alzheimer disease - approaching consensus.
Galasko D, Shaw L
Nat Rev Neurol. 2017; 13(3):131-132.
PMID: 28155892
PMC: 5912691.
DOI: 10.1038/nrneurol.2017.11.